Fundz

Luxinva to takeover QIAGEN NV for €10.8B

PRIVATEOct 22, 2026

Acquiring Company

Luxinva S.A

Acquired Company

QIAGEN

Abu DhabiFinancial ServicesBiotechnologyHealth CareScience And EngineeringInternet Services

Description

Luxinva S.A. has announced a voluntary public takeover offer for QIAGEN N.V. The offer values QIAGEN at approximately €10.8 billion and includes a premium of about 40.3%. The transaction is subject to certain conditions detailed in the Business Combination Agreement.

Who to call at Luxinva S.A, and when

When Luxinva S.A changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Luxinva S.A raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Luxinva S.A, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Luxinva S.A

Location

Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates

About

Luxinva S.A. is a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), involved in investments and financial services.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Luxinva S.A makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Luxinva S.A's next move

Learn about Strategic plan

Frequently asked

Who acquired QIAGEN?

QIAGEN was acquired by Luxinva S.A, based in Abu Dhabi. The deal was reported on October 22, 2026. Luxinva S.A. is a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), involved in investments and financial services. Luxinva S.A is privately held and operates in Financial Services.

When did Luxinva S.A acquire QIAGEN?

Luxinva S.A's acquisition of QIAGEN was reported on October 22, 2026. Luxinva S.A. has announced a voluntary public takeover offer for QIAGEN N.V. The offer values QIAGEN at approximately €10.8 billion and includes a premium of about 40.3%. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does QIAGEN do?

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. It is privately held, operating in Biotechnology.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.